SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 362 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $6,968,000 | -52.9% | 89,197 | -45.7% | 0.00% | -50.0% |
| Q4 2021 | $14,804,000 | -5.3% | 164,396 | -2.8% | 0.01% | -11.1% |
| Q3 2021 | $15,640,000 | +15.0% | 169,113 | -3.3% | 0.01% | +12.5% |
| Q2 2021 | $13,602,000 | +65.2% | 174,974 | +58.3% | 0.01% | +60.0% |
| Q1 2021 | $8,236,000 | -61.9% | 110,510 | -13.0% | 0.01% | -64.3% |
| Q4 2020 | $21,645,000 | +31.4% | 126,956 | +8.2% | 0.01% | +16.7% |
| Q3 2020 | $16,476,000 | -12.0% | 117,325 | +0.5% | 0.01% | -14.3% |
| Q2 2020 | $18,726,000 | +19.4% | 116,788 | -27.1% | 0.01% | 0.0% |
| Q1 2020 | $15,680,000 | -15.3% | 160,293 | +11.8% | 0.01% | 0.0% |
| Q4 2019 | $18,502,000 | +104.1% | 143,382 | +19.2% | 0.01% | +100.0% |
| Q3 2019 | $9,063,000 | -56.3% | 120,328 | -11.8% | 0.01% | -58.8% |
| Q2 2019 | $20,721,000 | +33.2% | 136,365 | +4.5% | 0.02% | +30.8% |
| Q1 2019 | $15,552,000 | +17.0% | 130,482 | +7.2% | 0.01% | 0.0% |
| Q4 2018 | $13,289,000 | -37.3% | 121,773 | -7.2% | 0.01% | -31.6% |
| Q3 2018 | $21,184,000 | +24.6% | 131,161 | +2.0% | 0.02% | +18.8% |
| Q2 2018 | $16,996,000 | +78.0% | 128,581 | -0.2% | 0.02% | +77.8% |
| Q1 2018 | $9,546,000 | +12.6% | 128,843 | -15.4% | 0.01% | +12.5% |
| Q4 2017 | $8,479,000 | +37.4% | 152,386 | +12.0% | 0.01% | +14.3% |
| Q3 2017 | $6,173,000 | +66.7% | 136,098 | +23.9% | 0.01% | +75.0% |
| Q2 2017 | $3,702,000 | +14.7% | 109,818 | +0.7% | 0.00% | -20.0% |
| Q1 2017 | $3,227,000 | +12.8% | 109,034 | +4.6% | 0.01% | +25.0% |
| Q4 2016 | $2,860,000 | -68.6% | 104,249 | -29.6% | 0.00% | -71.4% |
| Q3 2016 | $9,098,000 | +250.1% | 148,157 | +8.7% | 0.01% | +250.0% |
| Q2 2016 | $2,599,000 | +418.8% | 136,273 | +431.2% | 0.00% | +300.0% |
| Q1 2016 | $501,000 | +84.9% | 25,654 | +265.4% | 0.00% | – |
| Q4 2015 | $271,000 | -40.0% | 7,021 | -50.1% | 0.00% | -100.0% |
| Q3 2015 | $452,000 | +95.7% | 14,079 | +85.7% | 0.00% | – |
| Q2 2015 | $231,000 | +4.1% | 7,582 | -50.6% | 0.00% | – |
| Q4 2014 | $222,000 | -38.0% | 15,334 | +27.6% | 0.00% | -100.0% |
| Q2 2014 | $358,000 | +30.2% | 12,013 | +106.3% | 0.00% | 0.0% |
| Q3 2013 | $275,000 | – | 5,823 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |